Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management

E Sechi, L Cacciaguerra, JJ Chen, S Mariotto… - Frontiers in …, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges

A Al-Ani, JJ Chen, F Costello - Journal of Neurology, 2023 - Springer
New diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease
(MOGAD) have recently been proposed, distinguishing this syndrome from other …

Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?

B Chen, E Gomez‐Figueroa, V Redenbaugh… - Annals of …, 2023 - Wiley Online Library
Objective Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) can
be monophasic or relapsing, with early relapse being a feature. However, the relevance of …

An update on optic neuritis

JA Kraker, JJ Chen - Journal of Neurology, 2023 - Springer
Optic neuritis (ON) is the most common cause of subacute optic neuropathy in young adults.
Although most cases of optic neuritis (ON) are classified as typical, meaning idiopathic or …

Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: review of a novel clinico-radiographic spectrum

A Budhram, A Mirian, M Sharma - Frontiers in Neurology, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an
inflammatory demyelinating disease that is distinct from multiple sclerosis. Initial …

[HTML][HTML] MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity

SS Yandamuri, B Filipek, AH Obaid, N Lele… - JCI insight, 2023 - ncbi.nlm.nih.gov
Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is an
inflammatory demyelinating CNS condition characterized by the presence of MOG …

Humoral signatures of MOG-antibody-associated disease track with age and disease activity

M Spatola, O Chuquisana, W Jung, JA Lopez… - Cell Reports …, 2023 - cell.com
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is
an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in …

Myelin Oligodendrocyte Glycoprotein–Associated Disorders

E Longbrake - CONTINUUM: Lifelong Learning in Neurology, 2022 - journals.lww.com
PURPOSE OF REVIEW Anti–myelin oligodendrocyte glycoprotein (MOG) autoantibodies
have become a recognized cause of a pathophysiologically distinct group of central nervous …

Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a …

G Spagni, B Sun, G Monte, E Sechi, R Iorio… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background Rituximab (RTX) efficacy in patients with myelin oligodendrocyte glycoprotein
(MOG) antibody-associated disorders (MOGADs) is still poorly understood, though it …

Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study

J ZhangBao, W Huang, L Zhou, H Tan… - Journal of Neurology …, 2023 - jnnp.bmj.com
Background To identify factors associated with relapse risk and disability in myelin
oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Method Between …